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Introduction: In a previous biomarker discovery project using gene-
expression profiling we identified Serpin B3 (SB3) as a predictor of 
resistance to platinum doublet chemotherapy (PtC) in non–small-
cell lung cancer (NSCLC). This independent prospective study was 
designed to confirm the predictive utility of SB3.
Methods: SB3 immunohistochemistry was scored by previously 
validated criteria (score 0 = negative, score 1 = 1%–10% tumor 
cells positive, score 2 = 11%–50% tumor cells positive, and score 
3 = >50% tumor cell positive) in 197 patients with stage IV NSCLC 
treated with PtC. This provided 80% power to detect a median sur-
vival increase from 150 days in patients with an SB3 immunohisto-
chemistry score of 2 or more to 300 days in those with an SB3 score 
of 0 or 1.
Results: Thirty-six percent of NSCLCs stained positive for SB3. 
Median survival for SB3 negative/score 0 was 332 days, SB3 posi-
tive/score 1 was 268 days, and SB3 positive/score 2 or 3 was 120 
days (p = 0.004). Cox proportional hazards analysis demonstrated 
that SB3 positivity is an independent predictor of survival (hazard 
ratio = 1.87; 95% confidence interval, 1.29–2.71; p = 0.001).The dis-
ease control rate in SB3 score 0, 1 = 65%, and score of 2 or more = 
20 % (p = 0.002), with median survival 306 days (score 0, 1) versus 
120 days (score ≥2, hazard ratio= 1.71; 95% confidence interval. 
1.14–3.10; p = 0.002).
Conclusions: SB3-positive immunohistochemistry score of 2 or 
more (>10% tumor cells positive) identifies a subgroup of patients 
with stage IV NSCLC who have a poor survival (median 120 days) 
when treated with PtC, similar to that estimated for untreated or 
chemo-refractory stage IV NSCLC. Further prospective qualifica-
tion using biospecimens from randomized studies is needed, but SB3 
seems to be a useful biomarker that identifies a highly resistant sub-
group in whom PtC should be avoided.
Key Words: Biomarkers, Chemotherapy, Non–small-cell lung can-
cer, Serpin B3.
(J Thorac Oncol. 2013;8: 1502–1509)
The molecular characterization of non–small-cell lung can-cer (NSCLC) has enabled predictive biomarker directed use 
of targeted therapies.1 However, for the majority of patients a 
targeted therapy is not currently available and platinum (PtC) 
combination chemotherapy remains a key part of the systemic 
treatment in advanced-stage disease.2 Considering the toxicity 
of PtC, the avoidance of ineffective therapy is desirable, particu-
larly in the vulnerable group of patients with advanced NSCLC. 
Accordingly, preclinical and clinical investigation continues to 
identify predictive biomarkers for PtC in advanced NSCLC.3 
Putative predictive biomarkers for PtC in NSCLC include 
nucleotide excision repair components, most notably ERCC1 
for cisplatin and carboplatin,4–6 BRCA1 for cisplatin and car-
boplatin,7,8 and RRM1 for gemcitabine,9,10 class III β-tubulin 
for taxanes,7,11,12 p53 for cisplatin/vinorelbine,13 MSH2 for cis-
platin,14 p27 for cisplatin-based therapy15 and thymidylate syth-
etase for pemetrexed.16 However, despite extensive preclinical 
investigation and retrospective/prospective clinical investiga-
tion in advanced NSCLC, no reliable predictive biomarkers for 
PtC are recommended for clinical use,17,18 and there remains a 
clinical need for effective predictive biomarkers.
Previously we undertook a hypothesis-generating study 
using gene-expression profiling to discover new predictive 
biomarkers for PtC in NSCLC.19 Genes whose expression was 
significantly and consistently correlated with the response to 
PtC in patients with advanced NSCLC were identified and the 
derived gene-expression signature enabled prediction of the 
response phenotype.19 Within this signature, expression of the 
serine protease Serpin B3 demonstrated a strong correlation 
with response (p < 0.0001) so was selected as a lead predictive 
biomarker for PtC, and retrospectively qualified in an indepen-
dent set (n = 36) of advanced NSCLC using immunohisto-
chemistry (IHC). Characterization of Serpin B3 expression 
by IHC allowed a simple scoring system to be developed and 
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technically validated according to tumor cell positivity (tcp): 
Score 0=negative, score 1 = 1% to 10% tcp, score 2 = 10% to 
50% tcp, and score 3 of 50% or higher tcp.19 In an independent 
set of 36 advanced NSCLCs, use of the scoring system revealed 
a significant correlation between Serpin B3 protein expression 
and radiological response to PtC.19 Serpin B3 expression was 
associated with lack of response and no responses were seen in 
patients with Serpin B3 IHC scores of 2 or more (≥10% tcp), 
suggesting that this represented a chemoresistant subgroup and 
that Serpin B3 IHC could provide a clinically useful predictive 
biomarker for PtC in advanced NSCLC.
Serpin B3 is a serine protease that also inhibits a num-
ber of lysosomal cathepsins.20,21 The full physiological and 
pathological function of Serpin B3 is not fully elucidated but 
it is clear that it has an important role in the prevention of 
cell and tissue damage from proteolysis.20,21 Serpin B3 is over-
expressed in many human cancers, and preclinical studies in 
several types of cancer have shown that Serpin B3 inhibits cell 
death initiated by a wide variety of different stimuli including 
cytotoxic drugs such as cisplatin and etoposide.19,22–27 In breast 
cancer Serpin B3 overexpression is associated with resistance 
to anthracycline-based neoadjuvant chemotherapy.28 Serpin 
B3 also has demonstrated roles in epithelial to mesenchymal 
transition, prevention of airway damage in chronic inflam-
matory states and pulmonary fibrosis.22,29,30 Serpin B3 is 
expressed in the cytosol and can be detected in the serum of 
cancer patients because of passive overflow from tumor cyto-
sol as a result of overexpression rather than active secretion.31 
Accordingly, a role for Serpin B3 in mediating PtC resistance 
in NSCLC seems biologically plausible and the aim of the 
current study was to qualify the predictive utility of Serpin 
B3 in an adequately powered independent prospective cohort. 
We hypothesized that high Serpin B3 expression in NSCLCs, 
defined as more than 10% tumor cells positive in the immu-
nohistochemical assay (IHC score ≥2) would predict PtC 
resistance and poor survival, potentially providing a clinically 
useful biomarker by identifying a highly resistant subgroup of 
stage IV NSCLC patients in whom PtC should be avoided and 
alternative therapeutic strategies investigated.
PATIENTS AND METHODS
Patients and Treatment
The study proceeded with full ethical approval from the 
North of Scotland Research Ethics Committee complying with 
the principles of Good Clinical Practice and fully informed 
participant consent. Patients were eligible if they had a histo-
logical diagnosis of NSCLC (adenocarcinoma, squamous cell 
carcinoma, large cell carcinoma, or unspecified NSCLC), of 
stage IV (American Joint Committee on Cancer, 6th edition)32 
after standard computed tomography (CT) of neck, chest, and 
abdomen (magnetic resonance imaging and/or FDG-positron 
emission tomography CT permitted in equivocal cases) with 
adequate bone marrow, renal, and hepatic function for systemic 
chemotherapy, Eastern Cooperative Oncology Group perfor-
mance status of 0, 1, or 2, and adequate histological material had 
to be available for immunohistochemical analysis of Serpin B3. 
Exclusion criterion was any serious comorbid condition, which 
in the opinion of the treating physician excluded treatment with 
platinum combination chemotherapy. All potential patients 
were reviewed by the multidisciplinary team in the regional 
cancer center at Aberdeen Royal Infirmary, Scotland, to confirm 
eligibility. Because preclinical and clinical evidence, and the 
known biochemical, cellular, and physiological roles of Serpin 
B3 provide a biologically plausible explanation for its role in 
mediating resistance to cytotoxic drugs with a variety of differ-
ent mechanisms of action, we hypothesized a role for Serpin B3 
in mediating resistance to platinum-based chemotherapy com-
bining cisplatin with different cytotoxic drugs.19–31 Therefore, 
treatment was permitted with one of the following standard 






  Median 64
  Range 38–78
Sex
  Male 116
  Female 81
Smoker
  Ongoing 187
  Never 10
Performance status
  0 45
  1 137
  2 15
Histology
  Adenocarcinoma 86
  Squamous cell carcinoma 62
  Large cell carcinoma 30
  Unspecified 19
Weight loss
  >10% 75
  <10% 122
Platinum agent
  Cisplatin 128
  Carboplatin 69
Combination agent
  Docetaxel 62
  Gemcitabine 105
  Paclitaxel 4
  Pemetrexed 18
  Vinorelbine 8
Radiotherapy
  Yes 88
  No 109
Second-line treatment
  Erlotinib/gefitinib 33
  Chemotherapy 25
NSCLC, non–small-cell lung cancer.
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3-weekly cisplatin 75 mg/m2 (or carboplatin area under curve 
5 if contraindications to cisplatin) plus pemetrexed 500 mg/m2 
or gemcitabine 1250 mg/m2 day 1+8 or docetaxel 75 mg/m2, or 
paclitaxel 200 mg/m2, or vinorelbine 25 mg/m2/week and cis-
platin 100 mg/m2/d, day 1 every 28 days. Up to four cycles of 
treatment were permitted with clinical examination, hematolog-
ical and biochemical laboratory investigations and chest radio-
graph before each cycle. Dose modifications for toxicity were 
performed according to protocol and a restaging CT scan was 
performed after four cycles or earlier if tumor progression was 
suspected. In addition to progression, reasons to discontinue 
chemotherapy before four cycles included serious toxicity and 
patient/physician decision. Overall survival was defined as date 
of study entry until date of death, and response was assessed 
by Response Evaluation Criteria in Solid Tumors v1.0.33 After 
completion of chemotherapy, patients were followed up every 
6 to 12 weeks depending upon clinical condition, with physi-
cal examination and further investigations according to clinical 
need. Palliative radiotherapy or second-line treatment or was 
permitted excepting retreatment with cisplatin or carboplatin.
Immunohistochemistry
IHC was preformed according to the method previously 
described in detail and scored as before,19 using validated 
TABLE 2.  Seprin B3 IHC with Clinical, Histopathological, and Treatment Details of Patients (Fisher’s Exact Test)
Variable Serpin B3 IHC Serpin B3 IHC Score
Negative Positive p 0 and 1 ≥2 p
Age
  ≥Median (≥64 yr) 66 34 89 11
  <Median (<64 yr) 61 36 0.379 88 9 0.815
Sex
  Male 69 47 105 11
  Female 58 23 0.107 72 9 0.812
Smoking history
  Never smoker 4 0 4 0
  Smoker/ex-smoker 123 70 0.299 173 20 1.000
Histology
  Nonsquamous 97 38 120 15
  Squamous 30 32 0.002* 57 5 0.617
Platinum type
  Cisplatin 79 49 114 14
  Carboplatin 48 21 0.272 63 6 0.613
Second drug in regimen
  Taxane 43 23 60 6
  Nontaxane 84 47 1.000 117 14 0.807
Weight loss at presentation
  >10% 48 27 66 9
  <10% 79 73 1.000 111 11 0.628
WHO Performance status
  2 119 63 164 18
  0.1 8 7 0.404 13 2 0.653
Second-line systemic treatment
  Yes 44 13 50 7
  No 83 57 0.021* 127 13 0.604
T stage
  T1/2 49 26 66 9
  T3/4 78 44 0.879 111 11 0.628
N stage
  Node negative 8 6 13 1
  Node positive 119 64 0.571 164 19 1.00
Liver metastases
  Yes 21 8 29 0
  No 106 62 0.204 148 20 0.049*
*indicates significant P value.
IHC, immunohistochemistry; WHO, World Health Organization.
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criteria, namely score 0=negative, score 1 = 1% to 10% tcp, 
score 2 = 10% to 50% tcp, and score 3 of 50% or more tcp, 
regardless of staining intensity. Cases were scored indepen-
dently by two histopathologists and agreement was high with κ 
statistic = 0.92; p < 0.001. Scoring discrepancies were resolved 
by consensus after review of cases at a double-headed micro-
scope. Treating physicians and patients were blind to Serpin 
B3 score and scorers were blind to the treatment outcomes.
Statistical Analysis
Previously we saw no responses in 36 patients with 
advanced NSCLC who had a Serpin B3 IHC score of 2 or more. 
Responses were seen exclusively in those with a score of 0, or 
1.19 Accordingly, we hypothesized that patients with a Serpin B3 
IHC score of 2 or more would have chemoresistant tumors and 
a poor survival. Assuming that 12% of NSCLCs have an IHC 
score of 2 or more19 then considering α = 0.05, and a median sur-
vival for Serpin B3 patients, IHC score of 2 or more of 150 days 
consistent with their resistance to PtC, and 300 days in Serpin 
B3 IHC score of 0 and 1, then a cohort of 190 patients would 
provide a power of 0.80. Fisher’s exact test was used for cat-
egorical variables and Kaplan–Meier and Cox proportional haz-
ard model for survival analysis and all p values are two-sided. 
Statistical analysis was performed using SPSS statistics 20.
RESULTS
Clinical Features of Patients
One hundred ninety-seven patients were recruited between 
January 2008 and May 2010 (Table 1). A participant flow dia-
gram is shown in Supplementary Digital Content 1 (http://links.
lww.com/JTO/A485) in accordance with the Recommendations 
for Tumour Marker Prognostic Studies (REMARK) guidelines. 
Twenty-nine percent of patients received second-line systemic 
treatment and 45% palliative radiotherapy (Table 1). Median 
follow-up for patients still alive was 773 days.
Serpin B3 IHC
Positive Serpin B3 staining was seen in 36% of 
NSCLCs (70 of 197) in this cohort (25% [n = 50] score 
1 and 11% [n = 20] score 2 or 3) similar to our previous 
study.19 Representative examples of Serpin B3 IHC scores 
are provided in Supplementary Digital Content 2 (http://
links.lww.com/JTO/A486). Serpin B3 was more frequently 
positive in squamous histology (p < 0.002), but Serpin B3 
IHC score of 2 or more (the prespecified cutoff for treatment 
outcome prediction) was not more frequent in squamous 
histology (Table 2). Low (IHC score 1) or negative Serpin 
B3 was found more frequently in patients with liver metasta-
ses (p=0.049; Table 2). Serpin B3 positive patients received 
second-line therapy less often (p = 0.021), but there was no 
difference in the frequency of second-line chemotherapy in 
patients with Serpin B3 IHC score of 0 and 1 versus those 
with 2 or more (the prespecified cutoff for treatment outcome 
prediction). Serpin B3 IHC was not associated with age, sex, 
smoking history, performance status, weight loss, or type of 
chemotherapy treatment(Table 2).
Serpin B3 IHC and Overall Survival
Serpin B3 expression was strongly correlated with 
overall survival. Median survival according to Serpin B3 was: 













1506 Copyright © 2013 by the International Association for the Study of Lung Cancer
Urquhart et al. Journal of Thoracic Oncology ®  •  Volume 8, Number 12, December 2013
or 3 = 120 days (Fig. 1; log rank p = 0.004). Cox proportional 
hazards analysis demonstrated that Serpin B3 positivity is an 
independent predictor of survival (Table 3 hazard ratio [HR] 
= 1.87; 95% confidence interval [CI], 1.29–2.71; p = 0.001).
Applying the predefined stratification cutoff of Serpin 
B3 IHC score of 2 or more,21 median survival in patients with 
score 0 or 1 was 306 days and median survival in score of 2 
or more was 120 days (Fig. 2, HR= 1.71; 95% CI, 1.14–3.10; 
p = 0.002). Cox proportional hazards analysis demonstrated 
that Serpin B3 of 2 or more is an independent predictor of 
survival (Table 4; HR= 1.46; 95% CI, 1.11–2.91; p = 0.006).
Serpin B3 and Response to First-Line 
Platinum-Based Chemotherapy
Applying the predefined stratification cutoff, Serpin B3 
IHC score of 2 or more was associated with a worse disease 
control rate (disease control rate [DCR] = Response Evaluation 
Criteria in Solid Tumors partial response + complete response 
+ stable disease) to first-line PtC. The DCR in score 0 or 
1 = 65%, DCR in score 2or higher= 20%; p = 0.002).
DISCUSSION
An improved understanding of the molecular patho-
genesis of NSCLC together with the development of targeted 
therapies has led to the emergence of a molecular classifica-
tion for the disease where molecular abnormalities in tumors 
serve as predictive biomarkers to stratify patients for par-
ticular therapies.1 Current qualified predictive biomarkers in 
NSCLC, namely EGFR mutations and ALK rearrangements 
identify clinically effective targeted therapies for up to 20% 
of advanced-stage patients.34 Newly identified driver muta-
tions or molecular abnormalities amenable to targeting by 
agents in development may provide new therapeutic oppor-
tunities for a further 30% of NSCLCs.1,34 Therefore, at pres-
ent, a molecular target/predictive biomarker is not currently 
available for the majority of patients with NSCLC in whom 
PtC forms the systemic treatment of choice.2,17 Accordingly, 
predictive biomarkers for PtC in NSCLC are required in 
practice, especially considering the toxicity of chemotherapy 
and the need to avoid ineffective therapy in this vulnerable 
group of patients with limited life expectancy. Extensive 
investigation of predictive biomarkers for chemotherapy in 
NSCLC has, to date, failed to promote any marker into rou-
tine clinical use.17,18
Here we present a prospective, adequately powered, 
independent validation of the impact of Serpin B3 on the 
survival of advanced NSCLC patients treated with PtC by 
using a convenient, previously validated IHC assay and 
scoring system for Serpin B3,19 and using a hypothesis-
driven threshold to define biomarker-positive and -nega-
tive patients. In a biomarker discovery investigation we 
had previously identified that tumors positive for Serpin 
B3 using IHC tended to be resistant to PtC and also had a 
poor therapy independent prognosis.19 NSCLC patients with 
more than 10% of their tumor cells staining positively for 
Serpin B3 (IHC score ≥2), were invariably nonresponders.19 
Accordingly, we hypothesized that Serpin B3 could be a 
clinically useful predictive biomarker to identify patients 
whose tumors are resistant to PtC.
Our hypothesis is supported by this study and pro-
vides independent qualification of the predictive impact of 
Serpin B3 assayed by IHC in NSCLC. Patients who have 
stage IV NSCLC with Serpin B3 IHC score of 2 or more 
(≥ 10% tumor cells positive) are much less likely to achieve 
disease control (20% versus 65% p = 0.002), and have much 
shorter survival after treatment with PtC (120 days versus 
306 days; p = 0.002). Serpin B3 positive IHC, that is, any 
positive IHC staining versus negative, was found more fre-
quently in squamous cell carcinomas, but Serpin B3 IHC 
score of 2 or more (i.e., >10% tumor cells positive- the pre-
specified cutoff for treatment outcome prediction) was not 
more frequent in squamous histology(Table 2). Therefore an 
interaction between Seprin B3 IHC staining and histological 
subtype could not have influenced outcome or response to 
chemotherapy, for example, with pemetrexed, for the patient 
subgroups stratified by the prespecified and investigated bio-
marker cutoff of Serpin B3 IHC score of 2 or more. In addi-
tion, the multivariate analysis (Table 4) demonstrates that 




Variable HR (95% CI) p
Age 0.83 0.245
  ≥Median (0.60–1.14)
Smoking history 0.54 0.254
  Never smoker vs. smoker /ex-smoker (0.19–1.56)
Histology 1.05 0.801
  Squamous vs. nonsquamous (0.71–1.55)
Platinum type 0.73 0.085
  Cisplatin vs. carboplatin (0.51–1.05)
Second drug in regimen 0.90 0.156
  Taxane or nontaxane (0.77–1.04)
Disease control 0.22 <0.0001*
  CR + PR + SD vs. PD (0.15–0.32)
Weight loss at presentation 2.09 <0.0001*
  >10% vs. <10% (1.45–2.98)
WHO performance status 1.47 0.047*
  2 vs. 0.1 (1.05–1.99)
Second-line systemic treatment 0.84 0.360
  Yes vs. no (0.58–1.21)
T stage 1.05 0.594
  T1/2 vs. T3/4 (0.89–1.24)
N stage 1.22 0.033*
  Node positive vs. node negative (1.02–1.47)
Liver metastases 1.53 0.001*
  Yes vs. no (1.21–1.93)
Serpin B3 1.87 0.001*
  Positive (IHC score 1, 2, or 3) vs. 
negative (IHC score 0)
(1.29–2.71)
*indicates significant P value.
HR, hazard ratio; CI, confidence interval; CR, complete response; WHO, World 
Health Organization; PD, progressive disease; IHC, immunohistochemistry.
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overall survival independent of histology (squamous versus 
nonsquamous). Similarly, Serpin B3 positive IHC patients 
more commonly received second-line therapies, but second-
line treatment was not more common in Serpin B3 IHC score 
of 2 or more. Therefore, the frequency of second-line ther-
apy was not different between the groups of patients strati-
fied by the prespecified biomarker cutoff of Serpin B3 IHC 
score of 2 or more. Accordingly, differences in frequency of 
second-line therapy could not have influenced outcome in 
these Serpin B3 IHC stratified groups. Consistent with this, 
the multivariate analysis (Table 4) demonstrates that Serpin 
B3 IHC score of 2 or more is strongly associated with over-
all survival, independent of whether second-line therapy was 
given or not.
Serpin B3 IHC score of 2 or more identifies a sub-
group of approximately 10% NSCLC patients who have a 
median survival of only 120 days after treatment with PtC. 
Clinical experience and data from trials of chemotherapy 
versus best supportive care suggest that this survival profile 
of patients with Serpin B3 IHC score of 2 or more is very 
similar to those treated with supportive care only.35–39 The 
multivariate analysis demonstrates that Serpin B3 has utility 
independent of clinical features that are used by oncologists 
to determine patient selection for treatment, such as perfor-
mance status and weight loss. We suggest that Serpin B3 
IHC is a useful new predictive biomarker to select patients 
with advanced NSCLC in whom PtC would be ineffective 
and who might benefit more by treatment with other thera-
pies. Our study was prospective in terms of patient eligibil-
ity, treatment, follow-up, and outcome determination, used a 
previously validated assay for the biomarker Serpin B3 with 
a prespecified scoring system with a hypothesis-driven cut-
off for assay positivity versus negativity, and was adequately 
powered. However, without treatment randomization, the 
predictive versus the prognostic impact of Serpin B3 can-
not be definitively determined from this study.40 We have 
previously shown that Serpin B3 determined by using the 
same immunohistochemical assay has therapy-independent 
prognostic impact in resected NSCLC.19 The strong correla-
tion between Serpin B3 and response, with a DCR of 65% in 
Serpin B3 score 0 and 1 (<10% tumor cells positive at IHC), 
and only 20% in Serpin B3 IHC score of 2 or more (≥10% 
tumor cells positive at IHC; p = 0.002) suggests that the 
observed difference in survival is predominantly because of 
a predictive impact for PtC benefit. Evaluation of Serpin 
B3 in a prospective randomized controlled trial is needed 
to elucidate the prognostic versus predictive impact and in 
doing so, define precisely its clinical utility as a biomarker 
before clinical implementation or a prospective randomized 
trial where treatment was directed by Serpin B3 IHC as a 
biomarker could be undertaken. Considering the potential 
magnitude of the effect on DCRs and survival as observed 
in our study, there are a number of tumor specimen col-
lections from randomized trials including PtC and other 
non-PtC treatments arms (some of which are therapeutic 
trials and others which were designed primarily to deter-
mine biomarker utility) that would potentially be suitable 
and adequately powered to provide retrospective–prospec-
tive qualification.3,40 Nevertheless, whether predictive and/
or prognostic, the poor survival seen in patients with Serpin 
B3 IHC score of 2 or more here argues convincingly for 










1508 Copyright © 2013 by the International Association for the Study of Lung Cancer
Urquhart et al. Journal of Thoracic Oncology ®  •  Volume 8, Number 12, December 2013
of an IHC assay for Serpin B3 means that it can be readily 
performed on clinically available formalin-fixed, paraffin-
embedded biopsy material and would be feasible as part of 
a routine clinical histopathology service.
We are performing mechanistic studies using preclini-
cal models to determine the biology of Serpin B3 tumors to 
provide a rationale for suitable alternate targeted treatment 
approaches in NSCLC patients with Serpin B3 IHC score 
of 2 or more. In addition, we are performing mechanistic 
studies to determine the effect of overexpression of Serpin 
B3 on sensitivity to individual cytotoxic drugs, although our 
multivariate analyses suggests multidrug resistance. Our 
data, including the multivariate analysis, and other preclini-
cal and clinical evidence, as well as the known biochemical, 
cellular. and physiological roles of Serpin B3,19–31 suggests a 
role in mediating resistance to cytotoxic drugs with a vari-
ety of different mechanisms of action. This includes resis-
tance to platinum-based chemotherapy combining cisplatin 
with different cytotoxic drugs in NSCLC, which potentially 
increases the clinical utility and application of Serpin B3 as 
a biomarker. Investigation of Serpin B3 expression by IHC 
in tumor specimens from randomized controlled trials with 
different PtC regimens and other non-PtC treatments arms is 
necessary and would also assist in determination of the spe-
cific predictive impact of Serpin B3 for different individual 
cytotoxic drugs.
The identification by Serpin B3 IHC of a subgroup of 
NSCLC patients who do not benefit from PtC is potentially 
useful to avoid ineffective and harmful treatment with PtC in 
these patients. Ideally, alternative effective therapies would be 
available for Serpin B3 IHC score ≥ 2 patients as part of a 
biomarker-driven treatment protocol based on Serpin B3 IHC. 
Further in vitro and in vivo mechanistic investigation of the 
role of Serpin B3 in NSCLC pathogenesis and response to cur-
rently available targeted therapies is required before it would 
be possible to determine the most appropriate treatments for 
Serpin B3 IHC score of 2 or more NSCLC patients. Targeting 
Serpin B3 itself may be feasible, but again this requires fur-
ther mechanistic investigation.
In conclusion, we have shown that Serpin B3 positive 
IHC score of 2 (>10% tumor cells positive) identifies a sub-
group of patients with stage IV NSCLC who have a poor sur-
vival (median 120 days) and low probability of disease control 
when treated with PtC, which is similar to that estimated for 
untreated or chemo-refractory stage IV NSCLC. The magni-
tude of the effect seen suggests that Serpin B3 is a potential 
clinically useful predictive biomarker that identifies a highly 
resistant subgroup of advanced NSCLC patients in whom PtC 
should be avoided and that further prospective qualification in 
randomized studies is warranted to determine clinical utility.
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  Taxane or nontaxane (0.75–1.01)
Disease control 0.23 <0.0001*
  CR + PR + SD vs. PD (0.16–0.33)
Weight loss at presentation 1.77 0.002*
  >10% vs. <10% (1.23–2.53)
WHO performance status 1.52 0.019*
  2 vs. 0.1 (1.07–2.15)
Second-line systemic treatment 0.74 0.115
  Yes vs. no (0.51–1.08)
T stage 1.11 0.228
  T1/2 vs. T3/4 (0.94–1.32)
N stage 1.23 0.026*
  Node positive vs. node negative (1.03–1.48)
Liver metastases 1.53 0.001*
  Yes vs. no (1.21–1.94)
Serpin B3 1.46 0.006*
  IHC score ≥2 vs. 0 or 1 (1.11–2.91)
HR, hazard ratio; CI, confidence interval; CR, complete response; WHO, World 
Health Organization; PD, progressive disease; IHC, immunohistochemistry.
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